Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | ProCAID: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mCRPC

Simon Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, outlines the Phase II ProCAID (NCT02121639) trial investigating the combination of the pan-AKT inhibitor, capivasertib, plus docetaxel and prednisolone chemotherapy (DP) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The PI3K/ALT/PTEN is overactive in many mCRPC tumors which contributes to disease progression and resistance to DP, generating the rationale for this clinical trial. The primary endpoint was progression-free survival (PFS) in the intent-to-treat (ITT) population and the secondary endpoints included overall-survival (OS) and safety. The primary endpoint was negative, however a strong OS benefit was observed. The survival advantage is appearing to be maintained, specifically for patients who had received prior treatment with novel hormonal agents, such as abiraterone and enzalutamide. Dr Crabb hopes these results will evolve into a Phase III trial investigating docetaxel plus capiverstertib in patients with mCRPC following treatment with hormonal agents in the near future. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.